

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**

**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**

**“LURASIDONE HYDROCHLORIDE TABLETS”  
OBTAINED DRUG REGISTRATION CERTIFICATE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Lurasidone Hydrochloride Tablets” (trade name: Qing Li Xin (晴力欣)), a drug developed by the Group for treatment of schizophrenia, has been granted drug registration certificate by the National Medical Products Administration of China and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Lurasidone hydrochloride is an orally administered atypical antipsychotic drug, which is a 5-HT<sub>2A</sub> receptor and dopamine D<sub>2</sub> receptor antagonist. It has a high affinity for both 5-HT<sub>2A</sub> receptors and dopamine D<sub>2</sub> receptors. It also has a high affinity for 5-HT<sub>7</sub> and is a partial antagonist of the 5-HT<sub>1A</sub> receptor. Clinical studies have shown that lurasidone hydrochloride has significant benefits in improving both positive and negative symptoms of schizophrenia and reducing adverse effects. Compared with other atypical antipsychotics, it has the following advantages: (1) oral administration, convenient for patients; (2) weaker extrapyramidal response, less likely to cause adverse effects such as weight gain, hyperlipidaemia and hyperprolactinemia; and (3) potential advantages of improving cognitive ability, memory and mood.

The approval for launch of the Group's lurasidone hydrochloride tablets will provide schizophrenia patients in China with more economical and efficient medication options.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 14 March 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*